Title of article :
A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish head and neck cancer study (Dahanca) protocol 5–85: Overgaard J, Hansen HS, Ov
